Tecentriq

CONTENTS

6 OVERVIEW
6 Drug Overview
7 Product Profiles
7 Tecentriq : Breast cancer: triple-negative
16 Tecentriq : Hepatocellular carcinoma (HCC)
25 Tecentriq : Renal cell carcinoma (RCC)
36 Tecentriq : Non-small cell lung cancer (NSCLC)
54 Tecentriq : Melanoma
67 Tecentriq : Prostate cancer
77 Tecentriq : Colorectal cancer (CRC)
91 Tecentriq : Ovarian cancer
101 Tecentriq : Bladder cancer

LIST OF FIGURES
14 Figure 1: Datamonitor Healthcare’s drug assessment summary of Tecentriq for TNBC
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Tecentriq for TNBC
20 Figure 3: Datamonitor Healthcare’s drug assessment summary of Tecentriq for HCC
21 Figure 4: Datamonitor Healthcare’s drug assessment summary of Tecentriq for HCC
23 Figure 5: Tecentriq sales for HCC across the US, Japan, and five major EU markets, by country, 2018–27
30 Figure 6: Tecentriq for RCC – SWOT analysis
31 Figure 7: Datamonitor Healthcare’s drug assessment summary of Tecentriq for RCC
32 Figure 8: Datamonitor Healthcare’s drug assessment summary of Tecentriq for RCC
34 Figure 9: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country, 2017–26
45 Figure 10: Tecentriq for non-small cell lung cancer – SWOT analysis
46 Figure 11: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
47 Figure 12: Datamonitor Healthcare’s drug assessment summary for Tecentriq in non-small cell lung cancer
49 Figure 13: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
59 Figure 14: Tecentriq for melanoma – SWOT analysis
60 Figure 15: Datamonitor Healthcare’s drug assessment summary of Tecentriq for melanoma
61 Figure 16: Datamonitor Healthcare’s drug assessment summary of Tecentriq for melanoma
63 Figure 17: Tecentriq sales for melanoma across the US and five major EU markets, by country, 2017–26
70 Figure 18: Tecentriq for prostate cancer – SWOT analysis
71 Figure 19: Datamonitor Healthcare’s drug assessment summary of Tecentriq for prostate cancer
72 Figure 20: Datamonitor Healthcare’s drug assessment summary of Tecentriq for prostate cancer
74 Figure 21: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
82 Figure 22: Tecentriq for colorectal cancer – SWOT analysis
83 Figure 23: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
84 Figure 24: Datamonitor Healthcare’s drug assessment summary of Tecentriq for colorectal cancer
86 Figure 25: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country, 2016–25
96 Figure 26: Tecentriq for ovarian cancer – SWOT analysis
97 Figure 27: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
98 Figure 28: Datamonitor Healthcare’s drug assessment of Tecentriq for ovarian cancer
107 Figure 29: Tecentriq for urothelial bladder cancer – SWOT analysis
108 Figure 30: Datamonitor Healthcare’s drug assessment summary for Tecentriq in urothelial bladder cancer
109 Figure 31: Datamonitor Healthcare’s drug assessment summary for Tecentriq in urothelial bladder cancer

LIST OF TABLES
8 Table 1: Recent high-impact events for Tecentriq in TNBC
9 Table 2: Tecentriq drug profile
10 Table 3: Approval history of Tecentriq for TNBC in the US, Japan, and five major European markets
11 Table 4: Late-phase trials of Tecentriq for TNBC
13 Table 5: Tecentriq for TNBC – SWOT analysis
16 Table 6: Recent high-impact events for Tecentriq in HCC
17 Table 7: Tecentriq drug profile
18 Table 8: Trials of Tecentriq for HCC
19 Table 9: Tecentriq for HCC – SWOT analysis
26 Table 10: Tecentriq drug profile
27 Table 11: Tecentriq Phase III data in RCC
29 Table 12: Tecentriq Phase III trials in RCC
35 Table 13: Tecentriq sales for RCC across the US, Japan, and five major EU markets, by country ($m), 2017–26
36 Table 14: Tecentriq drug profile
38 Table 15: Tecentriq pivotal trial data in non-small cell lung cancer
40 Table 16: Tecentriq late-phase trial data in non-small cell lung cancer
43 Table 17: Tecentriq ongoing late-phase trial data in non-small cell lung cancer
50 Table 18: Tecentriq sales for NSCLC across the US, Japan, and five major EU markets, by country ($m), 2017–26
52 Table 19: Tecentriq patient numbers for NSCLC across the US, Japan, and five major EU markets, by country, 2017–26
55 Table 20: Tecentriq drug profile
56 Table 21: Tecentriq ongoing late-phase trials in melanoma
58 Table 22: Tecentriq early-phase data in melanoma
64 Table 23: Tecentriq sales for melanoma across the US and five major EU markets, by country ($m), 2017–26
66 Table 24: Tecentriq patient numbers for melanoma across the US and five major EU markets, by country, 2017–26
67 Table 25: Tecentriq drug profile
69 Table 26: Tecentriq Phase III trials in prostate cancer
75 Table 27: Tecentriq sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
77 Table 28: Tecentriq drug profile
79 Table 29: Tecentriq Phase III trial in colorectal cancer
81 Table 30: Tecentriq early-phase data in colorectal cancer
87 Table 31: Tecentriq sales for colorectal cancer across the US and five major EU markets, by country ($m), 2016–25
89 Table 32: Patients treated with Tecentriq in the US and five major EU markets, by country, 2016–25
92 Table 33: Tecentriq drug profile
93 Table 34: Tecentriq Phase III trials in ovarian cancer
95 Table 35: Overview of Phase I data for Tecentriq in ovarian cancer
102 Table 36: Tecentriq drug profile
104 Table 37: Tecentriq pivotal trial data in urothelial bladder cancer
105 Table 38: Tecentriq ongoing late-phase trials in urothelial bladder cancer